Wipfli Financial Advisors’s AbbVie ABBV Stock Holding History

Wipfli Financial Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$3.6M	Buy	+26,816	New	+$3.85M	0.25%	47

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wipfli Financial Advisors's ABBV Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in AbbVie (ABBV) in Q3 2022: 26,816 shares worth $3.6M. The stake represents 0.25% of the portfolio and ranks #47 among its holdings.

2,968 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

Wipfli Financial Advisors held 26,816 shares of AbbVie worth $3.6M as of Q3 2022.
AbbVie was a new Wipfli Financial Advisors position in Q3 2022.
AbbVie made up 0.25% of Wipfli Financial Advisors's portfolio in Q3 2022, its #47 holding.
2,968 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.